Atossa Genetics Inc. (NASDAQ:ATOS - Get Free Report)'s share price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.80 and traded as high as $0.85. Atossa Genetics shares last traded at $0.82, with a volume of 684,773 shares changing hands.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the stock. Ascendiant Capital Markets lifted their price target on shares of Atossa Genetics from $7.25 to $7.50 and gave the company a "buy" rating in a report on Friday, June 6th. Craig Hallum raised Atossa Genetics to a "strong-buy" rating and set a $4.00 price target for the company in a research report on Thursday, June 5th.
Check Out Our Latest Report on Atossa Genetics
Atossa Genetics Stock Performance
The business has a fifty day moving average of $0.85 and a 200-day moving average of $0.80. The firm has a market capitalization of $107.69 million, a P/E ratio of -3.97 and a beta of 0.92.
Atossa Genetics (NASDAQ:ATOS - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, equities research analysts forecast that Atossa Genetics Inc. will post -0.22 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Atossa Genetics
A number of large investors have recently made changes to their positions in ATOS. Y Intercept Hong Kong Ltd acquired a new position in Atossa Genetics during the second quarter worth $321,000. Renaissance Technologies LLC boosted its holdings in shares of Atossa Genetics by 18.9% during the 4th quarter. Renaissance Technologies LLC now owns 1,557,632 shares of the company's stock worth $1,471,000 after buying an additional 247,562 shares during the period. JPMorgan Chase & Co. grew its stake in Atossa Genetics by 141.4% in the 4th quarter. JPMorgan Chase & Co. now owns 361,296 shares of the company's stock valued at $341,000 after buying an additional 211,654 shares during the last quarter. Nuveen LLC bought a new position in Atossa Genetics in the 1st quarter worth $115,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Atossa Genetics by 40.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 422,582 shares of the company's stock worth $284,000 after acquiring an additional 120,934 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company's stock.
Atossa Genetics Company Profile
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Further Reading
Before you consider Atossa Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Genetics wasn't on the list.
While Atossa Genetics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
